Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

Diabetes, Obesity and Metabolism

Volumn 16, Issue 2, 2014, Pages 159-169

  Bolinder, J ^a   Ljunggren, O ^b   Johansson, L ^b,c   Wilding, J ^d   Langkilde, A M ^c   Sjostrom C D ^c   Sugg, J ^e   Parikh, S ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Adipose tissue; Bone mineral density; Fat; Metformin; Randomized trial; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE DISEASE; BONE TURNOVER; BREAST CANCER; BRONCHITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSURIA; EDEMA; ESOPHAGUS HEMORRHAGE; FAT MASS; FATIGUE; FEMALE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOMAGNESEMIA; KIDNEY DISEASE; LEG PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OSTEOPOROSIS; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE BLIND PROCEDURE; SPONDYLOSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; WAIST CIRCUMFERENCE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PHOTON ABSORPTIOMETRY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY MASS INDEX; BONE DENSITY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84892479365     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12189     Document Type: Article

References (26)

1. Brunton SA. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. Postgrad Med 2012; 124: 74-83.
2. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012; 14: 424-432.
3. Mudaliar S, Chang AR, Aroda VR et al. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes. Diabetes Obes Metab 2010; 12: 133-138.
4. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
5. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
6. Ferrannini E, Jimenez Ramos S, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010; 33: 2217-2224.
7. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
8. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
9. Gomis R, Owens DR, Taskinen MR et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract 2012; 66: 731-740.
10. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
11. Rosenstock J, Vico M, Wei L, Salsali A, List J. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes [Abstract 986-P]. Diabetes 2011; 60(Suppl. 1): A270.
12. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
13. Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
14. Rohwedder K, Hruba V, Salsali S et al. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has a low propensity to cause hypoglycemia in patients with type 2 diabetes. Diabetes 2011; 60(Suppl. 1): A286.
15. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
16. Ljunggren O, Bolinder J, Johansson L et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012; 14: 990-999.
17. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.
18. Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011; 152: 457-467.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Albanese CV, Diessel E, Genant HK. Clinical applications of body composition measurements using DXA. J Clin Densitom 2003; 6: 75-85.
21. Andreoli A, Scalzo G, Masala S, Tarantino U, Guglielmi G. Body composition assessment by dual-energy X-ray absorptiometry (DXA). Radiol Med 2009; 114: 286-300.
22. The International Society for Clinical Densitometry. Official positions. 2007. Available from URL: http://www.iscd.org/official-positions/4th-iscd-position-development-conference-adult/. Accessed 8 April 2013.
23. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 2008; 64: 707-715.
24. Pouilles JM, Tremollieres F, Ribot C. Variability of vertebral and femoral postmenopausal bone loss: a longitudinal study. Osteoporos Int 1996; 6: 320-324.
25. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
26. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28: 1173-1178.